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Figure 1:

Protein S (PS) is an anticoagulant molecule present in
humans and mice. Protein S binds and inhibits
coagulation Factor IXa to control thrombin generation1.
Protein S is imperative for normal hemostasis and the
prevention of life-threatening thrombotic events, as
demonstrated by numerous studies of patients with PS
deficiency2,3,4.
Pregnant women5 and women who use estrogencontaining birth control pills 6 have lower levels of PS.
Thus, it is postulated that estrogen downregulates PS
expression in humans. Because estrogen is synthesized
by aromatase, which is highly expressed in adipose
tissue7, we expect that PS will be downregulated in
obese mice and in mice treated with exogenous estrogen.
Further, we suggest that the downregulation effects of
obesity and estrogen on PS abundance will be
synergistic. Neither of these relationships have been
shown experimentally in a mouse model.
We used a thrombin generation assay (TGA) to measure
thrombin production in 24 mice weekly for six
consecutive weeks. Half of the mice were obese, and the
other half were lean. The obese mice were from a
transgenic line, gifted by our collaborator Dr. Laurent
Mosnier from Scripps Research Institute. The mice
remained obese while being fed a regular diet. Of the 12
obese mice, 6 were treated with a 1.7 mg pellet of
estradiol every 21 days, i.e., the obese + estrogen group
(OE); the other 6 mice constituted the obese-only (O)
group. Similarly, 6 lean mice were treated with estrogen
(LE), and the others were the untreated lean control (LC)
group. Plasma was collected via venipuncture and
centrifugation for each of the 5 weeks of treatment,
along with week 0 before estrogen treatment began.

Fig. 1: Thrombin Generation Assay shows increasing peak thrombin generated in OE, LE (excluding
week 5), and O as treatment progressed. OE had highest peak thrombin of all groups in every week, except
week 5 when O was slightly higher. Peak thrombin in LC remained very low throughout experiment.
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Fig. 2b: Western blot analysis for samples of interest
are illustrated in this bar graph. Samples 1993 (OE)
and 1679 (LE) had a marked decrease in Protein S
compared to control, supporting our hypothesis.
Sample 2000 (O) had a level comparable to control,
as did 1994 (OE) and 2216 (LE) – although these are
not shown in the graph. Since one sample (1999)
from the obese treatment group had a high level of
Protein S compared to control, we appreciate that
many factors are at play in the regulation of
coagulation, and we are hopeful that a stronger
correlation can be found as we continue to analyze
other samples.

The ELISA again showed that Protein S was lowest in the OE
sample. Here, the O sample was lower than the LE sample.
Unfortunately, we found that in this particular set of data, the LC
was equal to or lower than all treatment groups. Nonetheless, we
have many more samples to measure and are excited to compile
a larger pool of data.

Conclusion
Fig. 3: Here the results of
the capture ELISA are
demonstrated in a bar graph
with amount of Protein S
present, measured in percent
of control. OE (sample
2743) was lowest, in
congruence with our
hypothesis, followed by O
(sample 1998), then LE
(sample 993). However, all
of the treatment groups had
Protein S levels either
similar to or higher than the
control (sample 2206). More
investigation is needed to
confirm the trend seen in
this graph.

Finally, we assessed free Protein S in one sample from
each category, also from week 3, using capture ELISA.

The western blot highlighted lower Protein S in one OE sample
(40% of control) and one LE sample (61% of control). The other
bands were like the control, except one obese sample which was
very high in Protein S (249% of control). Transferrin was used as
a housekeeping gene and was accounted for in all calculations.

Of the 24 mice in the study, 2 died in week 2. Both of them were
from the OE group.

Figure 3:

We used SDS PAGE and western blot to compare the
level of Protein S in each treatment group to the level in
the control group. Week 3 samples were used because
there was some premature clotting in many of the weeks
4 and 5 samples.
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Fig. 2a: Western blot
showing total PS (upper
bands).

The results of the TGAs from each category and each week were
averaged and compiled into the graph shown in figure 1. Peak
thrombin was higher in all treatment groups compared to control,
and this difference generally became more pronounced the
longer treatment went on. OE had the highest peak thrombin in
all weeks, except week 5 when O was slightly higher. This may
be due to premature clotting in samples from week 5, which was
evident while pipetting. If clots formed in the serum before
thrombin was being measured, some of the clotting factors and
protein S would not be available for proper measurement.
Disregarding week 5, the TGAs show that peak thrombin is
abnormally high in obese mice as well as those treated with
estrogen, and even higher in the presence of both.
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